Envoy Medical (COCH)
Develops fully implanted hearing devices that use the natural ear as a sound sensor.
Something off on this page? Send us feedback.
Sells the FDA-approved Esteem fully implanted middle-ear implant and related replacements and care, while developing the investigational Acclaim fully implanted cochlear implant. Current revenue comes substantially from the Esteem installed base, while Acclaim depends on FDA approval and commercial scale-up.
Develops fully implanted hearing devices that use the natural ear to capture sound rather than an external microphone. Its FDA-approved Esteem active middle-ear implant serves adults with moderate-to-severe sensorineural hearing loss; implants, replacement components, programmers, batteries, and patient care arrangements produce substantially all current revenue.
Focuses development on Acclaim, an investigational fully implanted cochlear implant for adults with severe-to-profound sensorineural hearing loss not adequately addressed by hearing aids. Its commercialization depends on clinical follow-up, FDA approval, manufacturing scale-up, surgeon and clinic adoption, payer coverage, and sales of associated support.
Operates primarily in the United States, with final manufacturing in Minnesota and reliance on third parties for critical subassemblies. Reports a single hearing segment.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 21, 2026 | H.C. Wainwright | Reiterate | Buy | $2 | |
| Jul 27, 2026 | Loop Capital Markets | Target | $6 | $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $19.7M · Total debt $810.0K · Total assets $23.9M · Shareholders' equity $3.3M
- Revenue
- $51.0K
- Operating income
- −$5.6M
- Net income
- −$6.0M
No dividends on record.
| Institutions33 holders · as of Jun 30, 2026 | 22.97% | 17.73M shares | |
| Insiders6 holders · as of Jun 4, 2026 | 120.10% | 92.71M shares | |
| Adds to | 143.07% |
77.19M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (77.19M in the company's Sep 3, 2026 report, 20.80M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 143.07%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Glen A. Taylor1Insider10 percent owner | 117.38% | 68.91M · 21.70M | 13Dfiled Feb 17, 2026 ↗ |
Nantahala Capital Management, LLCInstitution | 9.91% | 7.65M | 13Fas of Jun 30, 2026 |
Bleichroeder LPInstitution | 8.10% | 6.25M | 13Fas of Jun 30, 2026 |
Charles BrynelsenInsiderdirector | 1.36% | 1.05M | Form 4filed Feb 17, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 1.14% | 880,214 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- Glen A. Taylor's transaction reports restate only vehicles that traded; the 2026 ownership statement (68.91M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 12, 2026 | Glen A. Taylor | 10 percent owner | +48,750,000 | $0.4000 |
| Feb 12, 2026 | Brent T. Lucas | director, officer: Chief Executive Officer | +162,500 | $0.4000 |
| Feb 12, 2026 | Charles Brynelsen | director | +2,600,000 | $0.4000 |
| Feb 12, 2026 | Susan Kantor | director | +249,990 | $0.4000 |
| Feb 12, 2026 | Robert Potashnick | officer: Interim CFO | +552,500 | $0.4000 |
Not reported.